RESUMO
Objective Donor countries either suspended or restricted development aid for Myanmar during the period of the military regime. However, the democratic movement, which began in 2011, gradually resolved this situation. The government of Myanmar organized a “Myanmar Development Cooperation Forum” in 2013, where the government demonstrated a path for the country’s future development to development partners, including donor countries, international organizations, and international funds. Furthermore, the government has increased the budget for the health sector and upheld universal health coverage (UHC), a target of Social Development Goals, as a goal for the future. To achieve that goal, the “National Health Plan 2017-2021” was recently formulated. This research attempts to identify issues that need to be considered by development partners in this changing environment.Methods The research was conducted through field studies and literature reviews to investigate the movements of both the government of Myanmar and development partners. It identified issues that need to be considered to achieve UHC, as well as those that development partners should consider when providing aid.Results and conclusion During the era of the Millennium Development Goals, development partners tended to focus their development aid on maternal and child health, control of specific diseases, and strengthening health services for those specific health problems. However, in order to extend health and medical services to all people, without financial risks on the part of patients under the goal of UHC, it is necessary for the government to formulate and execute comprehensive health policies based on an analysis of Myanmar’s health and medical problems. Aligning with this change, development partners need to concretize their support in response to Myanmar’s health policy issues.
RESUMO
Objective Donor countries either suspended or restricted development aid for Myanmar during the period of the military regime. However, the democratic movement, which began in 2011, gradually resolved this situation. The government of Myanmar organized a “Myanmar Development Cooperation Forum” in 2013, where the government demonstrated a path for the country’s future development to development partners, including donor countries, international organizations, and international funds. Furthermore, the government has increased the budget for the health sector and upheld universal health coverage (UHC), a target of Social Development Goals, as a goal for the future. To achieve that goal, the “National Health Plan 2017-2021” was recently formulated. This research attempts to identify issues that need to be considered by development partners in this changing environment.Methods The research was conducted through field studies and literature reviews to investigate the movements of both the government of Myanmar and development partners. It identified issues that need to be considered to achieve UHC, as well as those that development partners should consider when providing aid.Results and conclusion During the era of the Millennium Development Goals, development partners tended to focus their development aid on maternal and child health, control of specific diseases, and strengthening health services for those specific health problems. However, in order to extend health and medical services to all people, without financial risks on the part of patients under the goal of UHC, it is necessary for the government to formulate and execute comprehensive health policies based on an analysis of Myanmar’s health and medical problems. Aligning with this change, development partners need to concretize their support in response to Myanmar’s health policy issues.
RESUMO
Abnormal lipid metabolism associated with various renal diseases has been known for a long time. Hypercholesterolemia is one of the characteristic features of nephotic syndrome, and hypertriglyceridemia is often observed in chronic renal failure (CRF). The role of lipid abnormalities in the pathogenesis of renal diseases has been variously discussed. However, direct evidence only recently became possible when more sophisticated analyses of renal histopathology as well as an application of molecular biology were introduced in the field of clinical nephrology. The recent identification of lipoprotein nephropathy (LPG), reported most often by Japanese authors since 1989, is particularly noteworthy. The detailed analysis of lipid profiles and renal histology has been instrumental in clarifying the relationship between lipids and the kidney not only in LPG but also in other disease entities such as familial-type dyslipidemias, CRF, focal glomerulosclerosis, and diabetic nephropathy. Dyslipidemias common to these diseases, together with the presence of hypertension, cause systemic atherosclerotic lesions (including lesions in the kidney) and terminal renal failure.